- Home
- ABEO
as 05-16-2025 4:00pm EST
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
| Founded: | 1974 | Country: | United States |
| Employees: | N/A | City: | CLEVELAND |
| Market Cap: | 256.9M | IPO Year: | 1980 |
| Target Price: | $17.80 | AVG Volume (30 days): | 3.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.93 - $7.32 | Next Earning Date: | 05-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 383.07% |
Stock Insider Trading Activity of Abeona Therapeutics Inc. (ABEO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Seshadri Vishwas | ABEO | Chief Executive Officer | Mar 31 '25 | Sell | $4.78 | 25,000 | $119,500.00 | 1,355,322 |
Latest Abeona Therapeutics Inc. News
ABEO Breaking Stock News: Dive into ABEO Ticker-Specific Updates for Smart Investing
Associated Press Finance
a day ago
Abeona Therapeutics: Q1 Earnings Snapshot
GlobeNewswire
a day ago
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
GlobeNewswire
2 days ago
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
GlobeNewswire
2 days ago
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder
GlobeNewswire
2 days ago
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
Pharmaceutical Technology
3 days ago
Abeona secures cash runway with $155m priority review voucher sale
MT Newswires
4 days ago
Abeona Therapeutics to Sell Zevaskyn Priority Review Voucher for $155 Million; Shares Rise
GlobeNewswire
4 days ago
Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million
Compare ABEO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABEO Abeona Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.